CGRP抑制剂-话题@MedSci

#CGRP抑制剂#

6篇内容 | 705人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1573480, encodeId=2f0f15e348044, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, objectTitle=拯救偏头痛！CGRP抑制剂的发现之路, objectType=article, longId=202725, objectId=2530202e256b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2530202e256b, replyNumber=0, likeNumber=36, createdTime=2020-11-02, rootId=0, userName=zhaozuguo, userId=672515881410, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2530202e256b, moduleTitle=拯救偏头痛！CGRP抑制剂的发现之路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2530202e256b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573479, encodeId=5af015e34796d, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, objectTitle=美国FDA批准CGRP抑制剂Ubrelvy治疗急性偏头痛, objectType=article, longId=185147, objectId=e71018514e6b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e71018514e6b, replyNumber=0, likeNumber=29, createdTime=2019-12-26, rootId=0, userName=zhaozuguo, userId=672515881410, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e71018514e6b, moduleTitle=美国FDA批准CGRP抑制剂Ubrelvy治疗急性偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e71018514e6b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573478, encodeId=594215e347831, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, objectTitle=Lundbeck以近20亿美元收购Alder BioPharmaceuticals，获得CGRP抑制剂eptinezumab的权利, objectType=article, longId=179627, objectId=a28c1e962734, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a28c1e962734, replyNumber=0, likeNumber=19, createdTime=2019-09-19, rootId=0, userName=zhaozuguo, userId=672515881410, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a28c1e962734, moduleTitle=Lundbeck以近20亿美元收购Alder BioPharmaceuticals，获得CGRP抑制剂eptinezumab的权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a28c1e962734)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573477, encodeId=09ed15e34779a, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=21, createdTime=2019-07-03, rootId=0, userName=zhaozuguo, userId=672515881410, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573476, encodeId=ab4915e34763c, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, objectTitle=礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物, objectType=article, longId=167749, objectId=2b1416e7498d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b1416e7498d, replyNumber=0, likeNumber=34, createdTime=2019-06-07, rootId=0, userName=zhaozuguo, userId=672515881410, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b1416e7498d, moduleTitle=礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b1416e7498d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573475, encodeId=1a3115e3475a2, content=<a href='/topic/show?id=3aaf455863' target=_blank style='color:#2F92EE;'>#CGRP抑制剂#</a>, objectTitle=FDA或将批准CGRP抑制剂eptinezumab以预防偏头痛, objectType=article, longId=160996, objectId=36b71609964d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36b71609964d, replyNumber=0, likeNumber=33, createdTime=2019-02-26, rootId=0, userName=zhaozuguo, userId=672515881410, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36b71609964d, moduleTitle=FDA或将批准CGRP抑制剂eptinezumab以预防偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36b71609964d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CGRP抑制剂

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#CGRP抑制剂#

拯救偏头痛！CGRP抑制剂的发现之路

2020-11-02

zhaozuguo (审核中...)

前往app查看评论内容

#CGRP抑制剂#

美国FDA批准CGRP抑制剂Ubrelvy治疗急性偏头痛

2019-12-26

zhaozuguo (审核中...)

前往app查看评论内容

#CGRP抑制剂#

Lundbeck以近20亿美元收购Alder BioPharmaceuticals，获得CGRP抑制剂eptinezumab的权利

2019-09-19

zhaozuguo (审核中...)

前往app查看评论内容

#CGRP抑制剂#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2019-07-03

zhaozuguo (审核中...)

前往app查看评论内容

#CGRP抑制剂#

礼来的CGRP抑制剂Emgality喜获FDA批准，成为阵发性丛集性头痛的治疗药物

2019-06-07

zhaozuguo (审核中...)

前往app查看评论内容

#CGRP抑制剂#

FDA或将批准CGRP抑制剂eptinezumab以预防偏头痛

2019-02-26

科室
- - 订阅+
  - 更多科室
工具
服务